{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:53:28Z","timestamp":1761166408037,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"UMK","award":["450\/2017"],"award-info":[{"award-number":["450\/2017"]}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"crossref","award":["2014\/15\/B\/NZ7\/00930"],"award-info":[{"award-number":["2014\/15\/B\/NZ7\/00930"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jmgm.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T02:26:36Z","timestamp":1536373596000},"page":"171-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Docking and pharmacodynamic studies on hGAT1 inhibition activity in the presence of selected neuronal and astrocytic inhibitors. Part I"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-2369","authenticated-orcid":false,"given":"Alicja","family":"Nowaczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Fija\u0142kowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2018.09.003_bib1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s11055-014-9982-6","article-title":"Antiepileptic Drugs beyond Epilepsy (use of anticonvulsants in the treatment of pain syndromes)","volume":"44","author":"Davydov","year":"2014","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/eujp.2001.0324","article-title":"Anticonvulsants in neuropathic pain: rationale and clinical evidence","volume":"6","author":"Jensen","year":"2002","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.jmgm.2018.09.003_bib3","first-page":"1","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia, an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jmgm.2018.09.003_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy","volume":"22","author":"Landmark","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jmgm.2018.09.003_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ejps.2016.10.004","article-title":"Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors\u2014molecular docking and pharmacodynamic studies","volume":"96","author":"Fija\u0142kowski","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jmgm.2018.09.003_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.jmgm.2018.09.003_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.bjp.0706310","article-title":"Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain","volume":"146","author":"Winkler","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib8","first-page":"96","article-title":"Pregabalin can decrease acute pain and postoperative nausea and vomiting in hysterectomy: a meta-analysis","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.jmgm.2018.09.003_bib9","first-page":"96","article-title":"A\u00a0meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery","author":"Liu","year":"2017","journal-title":"Medicine"},{"issue":"18","key":"10.1016\/j.jmgm.2018.09.003_bib10","first-page":"30104","article-title":"Antiepileptic drugs as analgesics\/adjuvants in inflammatory pain: current preclinical evidence","author":"Tomi\u0107","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmgm.2018.09.003_bib11","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2174\/0929867324666170613075736","article-title":"Mechanisms of action, resistance and toxicity of insecticides targeting GABA receptors","volume":"24","author":"Buckingham","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib12","first-page":"1","article-title":"Kratom and future treatment for the opioids addiction and chronic pain: periculo beneficium?","volume":"18","author":"Ismaliza","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jmgm.2018.09.003_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pharep.2015.04.018","article-title":"The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice","volume":"67","author":"Sa\u0142at","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jmgm.2018.09.003_bib14","series-title":"Glial Amino Acid Transporters","first-page":"283","article-title":"Astrocytic GABA transporters: pharmacological properties and targets for antiepileptic drugs","author":"Schousboe","year":"2017"},{"key":"10.1016\/j.jmgm.2018.09.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2014.00161","article-title":"Structure, function, and plasticity of GABA transporters","volume":"8","author":"Scimemi","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jmgm.2018.09.003_bib16","series-title":"Pharmacology of GABA and Glycine Neurotransmission","first-page":"355","article-title":"Pharmacology of GABA transporters","author":"Clark","year":"2001"},{"key":"10.1016\/j.jmgm.2018.09.003_bib17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nurt.2010.05.016","article-title":"Targeting astrocyte signaling for chronic pain","volume":"7","author":"Gao","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jmgm.2018.09.003_bib18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pain.2013.06.022","article-title":"Glia and pain: is chronic pain a gliopathy?","volume":"154","author":"Ji","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.jmgm.2018.09.003_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainresrev.2004.03.003","article-title":"GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications","volume":"45","author":"Conti","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.jmgm.2018.09.003_bib20","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s11064-014-1263-9","article-title":"The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters","volume":"39","author":"Schousboe","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2015.05.002","article-title":"Molecular aspects of age-related cognitive decline: the role of GABA signaling","volume":"21","author":"McQuail","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jmgm.2018.09.003_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0197-0186(95)00158-1","article-title":"GABA transporter heterogeneity: pharmacology and cellular localization","volume":"29","author":"Borden","year":"1996","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jmgm.2018.09.003_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bcp.2004.06.041","article-title":"GABA transporters as drug targets for modulation of GABAergic activity","volume":"68","author":"Schousboe","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2017.12.003","article-title":"Astrocytes as therapeutic targets in brain diseases","volume":"126","author":"Hirase","year":"2018","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib25","series-title":"Handbook of Neurochemistry and Molecular Neurobiology","first-page":"285","article-title":"Functional and pharmacological aspects of GABA transporters","author":"Madsen","year":"2007"},{"key":"10.1016\/j.jmgm.2018.09.003_bib26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1023\/A:1007692012048","article-title":"Pharmacological and functional characterization of astrocytic GABA transport: a short review","volume":"25","author":"Schousboe","year":"2000","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pharmthera.2009.11.007","article-title":"Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs","volume":"125","author":"Madsen","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmgm.2018.09.003_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918783535","article-title":"Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway","author":"Xu","year":"2018","journal-title":"Mol. Pain"},{"key":"10.1016\/j.jmgm.2018.09.003_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11064-014-1504-y","article-title":"Role for pro-inflammatory cytokines in regulating expression of GABA transporter type 1 and 3 in specific brain regions of kainic acid-induced status epilepticus","volume":"40","author":"Su","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2016.07.012","article-title":"SLC6A1 mutation and ketogenic diet in epilepsy with myoclonic-atonic seizures","volume":"64","author":"Palmer","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4155\/fmc.10.288","article-title":"GABA transport inhibitors and seizure protection: the past and future","volume":"3","author":"Schousboe","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jnr.21499","article-title":"Hypoalgesia in mice lacking GABA transporter subtype 1","volume":"86","author":"Xu","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.ajp.0000110637.14355.77","article-title":"Tiagabine and gabapentin for the management of chronic pain","volume":"21","author":"Todorov","year":"2005","journal-title":"Clin. J. Pain"},{"year":"2009","series-title":"Gaussian 09,revision D.01","author":"Frisch","key":"10.1016\/j.jmgm.2018.09.003_bib34"},{"key":"10.1016\/j.jmgm.2018.09.003_bib35","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.jmgm.2018.09.003_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jct.2016.09.014","article-title":"The structure and diffusion behaviour of the neurotransmitter \u03b3-aminobutyric acid (GABA) in neutral aqueous solutions","volume":"104","author":"Rodrigo","year":"2017","journal-title":"J.\u00a0Chem. Thermodyn."},{"key":"10.1016\/j.jmgm.2018.09.003_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molstruc.2012.04.080","article-title":"Conformational preferences of \u03b3-aminobutyric acid in the gas phase and in water","volume":"1024","author":"Song","year":"2012","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.jmgm.2018.09.003_bib38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature03978","article-title":"Crystal structure of a bacterial homologue of Na+\/Cl--dependent neurotransmitter transporters","volume":"437","author":"Yamashita","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jmgm.2018.09.003_bib40","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1124\/mol.106.026120","article-title":"Comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter\/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function","volume":"70","author":"Beuming","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/nar\/gkg095","article-title":"The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003","volume":"31","author":"Boeckmann","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib42","doi-asserted-by":"crossref","first-page":"D336","DOI":"10.1093\/nar\/gkt1144","article-title":"ModBase, a database of annotated comparative protein structure models and associated resources","volume":"42","author":"Pieper","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jmgm.2018.09.003_bib44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cmdc.201000100","article-title":"Homology modelling of the GABA transporter and analysis of tiagabine binding","volume":"5","author":"Skovstrup","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jmgm.2018.09.003_bib45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/1386207319666160927111347","article-title":"SAnDReS a computational tool for statistical analysis of docking results and development of scoring functions","volume":"19","author":"Xavier","year":"2016","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.jmgm.2018.09.003_bib46","first-page":"0","article-title":"Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review","volume":"27","author":"Strac","year":"2015","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.jmgm.2018.09.003_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3565(25)05180-8","article-title":"Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jmgm.2018.09.003_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2015.07.037","article-title":"Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor","volume":"99","author":"Sa\u0142at","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jmgm.2018.09.003_bib49","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s11064-017-2188-x","article-title":"Delineation of the role of astroglial GABA transporters in seizure control","volume":"42","author":"Schousboe","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib50","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.bmc.2015.03.060","article-title":"Structure activity relationship of selective GABA uptake inhibitors","volume":"23","author":"Vogensen","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0741-8329(99)00086-5","article-title":"Design and structure-activity relationship analysis of ligands of gamma-hydroxybutyric acid receptors","volume":"20","author":"Bourguignon","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.jmgm.2018.09.003_bib52","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/jm00064a005","article-title":"The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4, 4-bis (3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate","volume":"36","author":"Andersen","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2005.11.005","article-title":"Glutamate-and GABA-based CNS therapeutics","volume":"6","author":"Foster","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib54","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2174\/156802606778249801","article-title":"Structure-activity relationships of selective GABA uptake inhibitors","volume":"6","author":"Hog","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib55","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1039\/C4CP00671B","article-title":"Conformation of the neurotransmitter \u03b3-aminobutyric acid in liquid water","volume":"16","author":"Ottosson","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jmgm.2018.09.003_bib56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cmdc.201500534","article-title":"Different binding modes of small and large binders of GAT1","volume":"11","author":"Wein","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jmgm.2018.09.003_bib57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3891\/acta.chem.scand.30b-0542","article-title":"X-ray crystallographic and proton magnetic resonance spectroscopic investigations of nipecotic acid, a potent inhibitor of \u03b3-aminobutyric acid (GABA) uptake","volume":"30","author":"Brehm","year":"1976","journal-title":"Acta Chem. Scand. B"},{"key":"10.1016\/j.jmgm.2018.09.003_bib58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00232-015-9778-9","article-title":"Permeability of the blood\u2013brain barrier: molecular mechanism of transport of drugs and physiologically important compounds","volume":"248","author":"Fong","year":"2015","journal-title":"J.\u00a0Membr. Biol."},{"key":"10.1016\/j.jmgm.2018.09.003_bib59","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/jm00112a032","article-title":"GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative","volume":"34","author":"N'Goka","year":"1991","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00240816","article-title":"Inhibitors of the GABA uptake systems","volume":"31","author":"Krogsgaard-Larsen","year":"1980","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm00151a001","article-title":"Stereoselective syntheses of the trans-decahydroquinoline-5-carboxylic acid epimers. Diastereomeric zwitterionic probes of. gamma.-aminobutyric acid-related biological properties in\u00a0vitro and in\u00a0vivo","volume":"29","author":"Witiak","year":"1986","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib62","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.1975955","article-title":"Cloning and expression of a rat brain GABA transporter","volume":"249","author":"Guastella","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jmgm.2018.09.003_bib63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/prot.10567","article-title":"N-H. O, O-H\u2026 O, and C-H\u2026 O hydrogen bonds in protein\u2013ligand complexes: strong and weak interactions in molecular recognition","volume":"54","author":"Sarkhel","year":"2004","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.jmgm.2018.09.003_bib64","doi-asserted-by":"crossref","first-page":"16132","DOI":"10.1021\/jp053416d","article-title":"Relative strengths of NH...O and CH...O hydrogen bonds between polypeptide chain segments","volume":"109","author":"Scheiner","year":"2005","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.jmgm.2018.09.003_bib65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/js980302n","article-title":"Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs","volume":"88","author":"Bonina","year":"1999","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.jmgm.2018.09.003_bib66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00964041","article-title":"Comparison between (RS)-nipecotic acid and GABA transport in cultured astrocytes: coupling with two sodium ions","volume":"6","author":"Larsson","year":"1981","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jmgm.2018.09.003_bib67","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1016\/j.bmcl.2013.10.058","article-title":"Design, synthesis and biological evaluation of \u03b1-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors","volume":"15","author":"Axford","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"volume":"vol. 22","year":"1985","author":"Ellis","key":"10.1016\/j.jmgm.2018.09.003_bib68"},{"key":"10.1016\/j.jmgm.2018.09.003_bib69","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1021\/jm301872x","article-title":"Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization","volume":"56","author":"Vogensen","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jmgm.2018.09.003_bib70","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pharep.2014.11.003","article-title":"Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression","volume":"67","author":"Sa\u0142at","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jmgm.2018.09.003_bib71","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2016.10.019","article-title":"Novel, highly potent and in\u00a0vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties","volume":"113","author":"Sa\u0142at","year":"2017","journal-title":"Neuropharmacology"}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326318304170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326318304170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:59:53Z","timestamp":1761080393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326318304170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":71,"alternative-id":["S1093326318304170"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2018.09.003","relation":{},"ISSN":["1093-3263"],"issn-type":[{"type":"print","value":"1093-3263"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docking and pharmacodynamic studies on hGAT1 inhibition activity in the presence of selected neuronal and astrocytic inhibitors. Part I","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}